Send to

Choose Destination
Med Sci (Paris). 2019 May;35(5):431-439. doi: 10.1051/medsci/2019076. Epub 2019 May 22.

[Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study].

[Article in French]

Author information

Inserm U1052, CNRS UMR 5286, Centre de recherche en cancérologie de Lyon (CRCL), Université de Lyon (UCBL), 151, cours Albert Thomas, 69008 Lyon, France.
Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France.
Division of Digestive Diseases, St Mary's Hospital, Imperial College London, London, Royaume-Uni.
Medical Research Council Laboratories, The Gambia Unit, Fajara, Gambie.
Department of bacteriology and Virology, CHU Le Dantec, Dakar, Sénégal.
Department of Internal Medicine, Jos University Teaching Hospital, Jos, Nigéria.
International Agency for Research on Cancer (IARC), Lyon, France.


Despite the existence of an effective vaccine, HBV infects 257 million people worldwide and is the cause of the majority of HCC. With an annual mortality rate of 887 000 patients in 2015, this cancer is the second deadliest. Low-income countries such as ones in sub-Saharan Africa are the most at risk due to the limited access to healthcare. To overcome this and born from an international research collaboration within an EU project, the Prolifica study aimed at evaluating a screen-and-treat program to prevent HBV complications, and more particularly HCC. Based on communities, facilities and hospitals HBsAg+ detection, the study lasted from 2011 to 2016. From the "cost effectiveness" feasibility of such a program to the development of simple scores for antiviral treatment, Prolifica uncovered data of crucial importance in a region with low HBV infection awareness, transmissions modes and prevention means which could have impacts on public health policies.

Free full text

Supplemental Content

Full text links

Icon for EDP Sciences Icon for London School of Hygiene and Tropical Medicine
Loading ...
Support Center